Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Uranium Energy Corp — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B), while Uranium Energy Corp trades at $9.38 (market cap $4.53B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 13× Uranium Energy Corp's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Uranium Energy Corp for 37 Days on average.
| TAK | UEC | |
|---|---|---|
Market Cap | $58.74B | $4.53B |
Volume | 3,110,994 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $19.05 | $20.14 |
52-Week Low | $13.23 | $9.04 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $86.65B | $4.03B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a net income margin of -368.62% and has missed earnings expectations in recent quarters. However, the company is expanding production capacity with two operational mines and benefits from growing U.S. government demand for domestic uranium.
While analyst consensus remains strongly bullish with an 87.5% buy rating and $16.06 price target, fundamental challenges persist including negative cash flow from operations and unproven production sustainability. The stock faces execution risks as it scales operations, but long-term uranium demand tailwinds provide potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
